Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"That clinical trials website lists that one phase 2 Nash trial is supposed to finish this October. The other one is listed to be completed in November. Do you think they will post the results soon after or will Oramed need a few months to go through the data before announcing the results?"
Hard to say. Technically, they are to report material news events in a timely manner but I've seen companies hang on to results for months "clarifying and collecting" results. The best indication for quick reporting is that this company does an outstanding job of communicating with shareholders. These results might be held for a medical conference which always provides credibility and perhaps more publicity. GL.
You can get a lot of information regarding the trial at clinicaltrials.gov. Just search on the trial name.
250,000,000 divided by $15 = 16,666,666 shares
Canaccord Genuity initiated coverage on Oramed Pharmaceuticals with a new price target. $27/share.
Who has an explanation for the incredible volume and price swings yesterday and today. The news is nice, but why didn't the price stick?
Let's be real. Its great that some progress is being made but its February 11th and we are getting much closer to a capital raise. The other posters are right, this raise is overhanging the stock like a cloud.
Not holding $3 today is worrisome. What catalyst can advance the stock in these conditions in the near term? Updated PC results? Maybe, but no conference appearance has been indicated. Love the technology but everything points to a lower/stagnant stock price in the short run. GLTA.
If interested, look at CorMedix (CRMD). Submitting their rolling NDA and stock trading at a level seen 2 years ago. Institutions adding. Strong likelihood of approval.
If he's a former Dendreonite, he knows what he is talking about.
This makes sense to me (from luckijack on the InvestorVillage mb)...
"bottom in?
Ok, at least the first bottom is in.
Though the recent drop is pretty devastating for stockholders, the stock dropped dramatically since Mid-September, then at $6. This I attributed initially to some inside info on the clinical hold (in spite the fact the hold cause appears not major). However in looking closer at the stock/warrant deal of last year the merger in October, it becomes clear the run last year to $10 was merger related (announced in May I think) and that trading since has been greatly affected by the shares and warrants put on in October. 13.9 million shares to Marker insiders and the Private Placement of 17.5 million shares -- each with warrants. The private placement was at $4.11 per share, and it included 13.4 million warrants, 5 year at exercise of $5.
Now, without going to a warrant calculator, those warrants were worth over a dollar. So, effective price of the shares was about $3. This leads, led, to a situation of selling of shares along the way, or shorting the warrants, lotsa fun stuff -- at prices lower than the then stock price. Increase in short position this year about 3.5 million shares, I submit virtually all is from shorting the warrants -- it is a beautiful place to be where you can short your warrants and if need be cover with your own shares, better yet if you can cover with someone else's shares. Anyway, now it looks to me like this is much of the trading, and it got an assist to the downside with the clinical hold.
The plus side, there are a lot of good institutional holders in this stock. Some got in with the private placement and will remain in. But, good does not mean they won't use those warrants to maximize profits or minimize risk.
I did add.......
jack"
https://www.investorvillage.com/smbd.asp?mb=18806&mn=471&pt=msg&mid=20006596
mauiguy2 - another aside, most brokerages figure all this out for you. I just download the tax stuff from my brokerage account at the end of the year, load it into TurboTax or TaxCut and let the tax program take care of it. Example, the brokerage will adjust the basis of your securities when it encounters a wash sale that prevents you from realizing a loss. Have been doing this for years and no problems. Perhaps someone else has some insights if I am mistaken.
When the question was asked of Dr. Pants regarding what would be needed for a Phase II trial approval he stated,
"Anything over a 2 month progression free survival would be approvable in a phase II trial."
Thanks for your post. Its nice to have a dose of reality from time to time.
I am 66 years old, a former options market maker and have been in these situations many times. Have given in to the "fear" several times and always regretted it. Hang tough amigos. This will pass.
Posts are sounding a litte panicky. Bought another 2,000 shares. GL.
Is anyone attending the plenary session Saturday?
This new stock will never reach the market. My guess is that there are buyers lined up around the block. Yes it is dilutive, but it may never impact the stock price. GL.
FYi, 80% of cancers are solid tumor cancers.
erg61...Any reasonable thoughts as to why the s/p is where it’s at?
Here's my thoughts (hopefully reasonable). After investing in several biotechs over many years, I am convinced that algorithmic based computer programs, or market makers, or big pocket players control individual stock prices on most days in most early stage biotechs. The typical pattern after good news is released is that the stock makes a huge jump. There are no investors selling who are in the stock for the long term. The selling comes from the entities previously mentioned. They then wait for the inevitable low volume down day to drive the price down, and keep it down until their short sales are repurchased. These entities make money on volatility, not when stocks sit still. Early stage biotechs have no earnings, dividends or other impetus to keep the stock price somewhat stable. True value is only recognized when another company makes a bid for MRKR or MRKR starts sales. Even this is no guaranty. There have been periods in stock market history where stocks sold for less than their book value. The only investing method that works is to buy cheaply and hang on for dear life. Like Buffet said, "Buy when there is blood in the streets."
One poster mentioned that there isn't much likelihood of news in the 1st qtr. This is a prescription for a slowly declining stock price in this type of stock. GLTA. Looking to buy in the near future.
Potentially sticking a toe in the water here but can anyone comment on their financial position? Outstanding debt? Cash on hand? What is the likelihood of the need to raise additional funds in 2019? TIA